Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a New Activator of KCa2 and KCa3.1 Potassium Channels, Potentiates the Endothelium-Derived Hyperpolarizing Factor Response and Lowers Blood Pressure

Ananthakrishnan Sankaranarayanan, Girija Raman, Christoph Busch, Tim Schultz, Pavel I. Zimin, Joachim Hoyer, Ralf Köhler and Heike Wulff
Molecular Pharmacology February 2009, 75 (2) 281-295; DOI: https://doi.org/10.1124/mol.108.051425
Ananthakrishnan Sankaranarayanan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Girija Raman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christoph Busch
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tim Schultz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pavel I. Zimin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joachim Hoyer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ralf Köhler
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heike Wulff
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Abstract

Small-conductance (KCa2.1-2.3) and intermediate-conductance (KCa3.1) calcium-activated K+ channels are critically involved in modulating calcium-signaling cascades and membrane potential in both excitable and nonexcitable cells. Activators of these channels constitute useful pharmacological tools and potential new drugs for the treatment of ataxia, epilepsy, and hypertension. Here, we used the neuroprotectant riluzole as a template for the design of KCa2/3 channel activators that are potent enough for in vivo studies. Of a library of 41 benzothiazoles, we identified 2 compounds, anthra[2,1-d]thiazol-2-ylamine (SKA-20) and naphtho[1,2-d]thiazol-2-ylamine (SKA-31), which are 10 to 20 times more potent than riluzole and activate KCa2.1 with EC50 values of 430 nM and 2.9 μM, KCa2.2 with an EC50 value of 1.9 μM, KCa2.3 with EC50 values of 1.2 and 2.9 μM, and KCa3.1 with EC50 values of 115 and 260 nM. Likewise, SKA-20 and SKA-31 activated native KCa2.3 and KCa3.1 channels in murine endothelial cells, and the more “drug-like” SKA-31 (half-life of 12 h) potentiated endothelium-derived hyperpolarizing factor-mediated dilations of carotid arteries from KCa3.1(+/+) mice but not from KCa3.1(-/-) mice. Administration of 10 and 30 mg/kg SKA-31 lowered mean arterial blood pressure by 4 and 6 mm Hg in normotensive mice and by 12 mm Hg in angiotensin-II-induced hypertension. These effects were absent in KCa3.1-deficient mice. In conclusion, with SKA-31, we have designed a new pharmacological tool to define the functional role of the KCa2/3 channel activation in vivo. The blood pressure-lowering effect of SKA-31 suggests KCa3.1 channel activation as a new therapeutic principle for the treatment of hypertension.

Footnotes

  • This work was supported by the National Institutes of Health National Institute of Neurological Disorders and Stroke [Grant R21-NS052165] and the Deutsche Forschungsgemeinschaft [Grants from project A11 of SFB 593 and KO1899/10-1].

  • H.W. and R.K. contributed equally to this work.

  • ABBREVIATIONS: KCa, Ca2+-activated K+ channel; EDHF, endothelium-derived hyperpolarizing factor; ACh, acetylcholine; CA, carotid artery; CAEC, carotid artery endothelial cell; HPLC, high-performance liquid chromatography; RT, room temperature; MS, mass spectrometry; NMDA, N-methyl-d-aspartate; DMSO, dimethyl sulfoxide; HERG, human ether-a-go-go-related gene; HEK, human embryonic kidney; PBS, phosphate-buffered saline; MOPS, 3-(N-morpholino)propanesulfonic acid; TLC, thin-layer chromatography; WT, wild type; EBIO, 1-ethylbenzimidazolin-2-one; Kv, voltage-gated K+ channel; MAP, mean arterial pressure; NS8593, N-[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]-1H-benzimidazol-2-amine hydrochloride; riluzole, 2-amino-6-[trifluoromethoxy]benzothiazole; SKA-1, 2-aminobenzothiazole; SKA-2, 2-amino-6-methoxybenzothiazole; SKA-3, 2-amino-6-chlorobenzothiazole; SKA-4, 2-amino-6-nitrobenzothiazole; SKA-5, 2-mercapto-5-methoxybenzothiazole; SKA-6, 2-amino-6-nitrobenzothiazole; SKA-7, 2-amino-6-benzylbenzothiazole; SKA-8, 2-amino-5-trifluoromethoxybenzothiazole; SKA-11, 2-amino-6-[chlorodifluoromethoxy]benzothiazole; SKA-12, 5-trifluoromethoxy-1H-benzimidazol-2-amine; SKA-13, 5-chloro-6-methoxy-benzothiazol-2-amine; SKA-16, 2-amino-6-[methylsulfonyl]benzothiazole; SKA-17, 5,6-dimethoxy-1,3-benzothiazol-2-amine; SKA-18, 2-amino-6-fluorobenzothiazole; SKA-19, 2-amino-6-trifluoromethylthio-benzothiazole; SKA-20, anthra[2,1-d]thiazol-2-ylamine; SKA-21, 2-amino-6,11-dihydro-6,11-dioxoanthra[2,1-d]-thiazole; SKA-22, 2-amino-6-benzoylbenzothiazole; SKA-24, 6-acetyl-2-aminobenzothiazole; SKA-25, 2-aminobenzo[1,2-d:4,3-d′]bisthiazole; SKA-26, 2-amino-7H-pyrano[2,3-g]benzothiazol-7-one; SKA-29, 6,7-dihydro-5H-indeno[5,6-d]thiazol-2-amine; SKA-30, 6,7-dihydro[1,4]dioxino[2,3-f]-[1,3]benzothiazol-2-amine; SKA-31, naphtho[1,2-a]thiazol-2-ylamine; SKA-32, 2-amino-6-phenoxybenzothiazole; SKA-34, 2-amino-5-trifluoromethyl)-benzothiazole; SKA-35, 2-amino-6-(trifluoromethoxy)benzothiazole; SKA-36, 2,6-diaminobenzothiazole; SKA-41, 4-(4-trifluoromethoxyphenyl)thiazol-2-amine; SKA-42, 2-amino-5,6-difluorobenzothiazole; SKA-44, 2-amino-6,7,8,9-tetrahydronaphtho[2,1-d]thiazole; SKA-45, naphtho[2,1-d]thiazol-2-amine; SKA-46, 5-trifluoromethoxy-1,3-dihydro-2H-benzimidazol-2-thione; SKA-47, 5-[difluoromethoxy]-2-mercapto-1H-benzimidazole; SKA-48, 2-amino-5,6-dimethoxybenzothiazole; SKA-49, 6,7,8,9-tetrahydronaphtho[1,2-d]thiazol-2-amine; SKA-50, 2,6-diaminobenzo[1,2-d:4,5-d′]bisthiazole; SKA-51, 2-amino-6-[trifluoromethyl]benzothiazole; SKA-53, 2-amino-6-methyl-benzo[1,2-d. 5,4-d′]bisthiazole; SKA-56, thiazolo[4,5-c]quinolin-2-ylamine; UCL1684, 6,10-diaza-3(1,3),8(1,4)-dibenzena-1,5(1,4)-diquinolinacyclodecaphane; UCL1848, 8,14-diaza-1,7(1,4)-diquinolinacyclotetradecaphane; MDL105519, (E)-3-(2-phenyl-2-carboxyethenyl)-4,6-dichloro-1H-indole-2-carboxylic acid; TRAM-34, 1-[(2-chlorophenyl)diphenylmethyl]-1H-pyrazole; NS309, 6,7-dichloro-1H-indole-2,3-dione 3-oxime; CGP-39653, (E)-2-amino-4-propyl-5-phosphono-3-pentenoic acid; ICA-17043, bis(4-fluorophenyl)phenylacetamide.

  • ↵ Embedded Image The online version of this article (available at http://molpharm.aspetjournals.org) contains supplemental material.

    • Received August 15, 2008.
    • Accepted October 27, 2008.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 75 (2)
Molecular Pharmacology
Vol. 75, Issue 2
1 Feb 2009
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a New Activator of KCa2 and KCa3.1 Potassium Channels, Potentiates the Endothelium-Derived Hyperpolarizing Factor Response and Lowers Blood Pressure
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a New Activator of KCa2 and KCa3.1 Potassium Channels, Potentiates the Endothelium-Derived Hyperpolarizing Factor Response and Lowers Blood Pressure

Ananthakrishnan Sankaranarayanan, Girija Raman, Christoph Busch, Tim Schultz, Pavel I. Zimin, Joachim Hoyer, Ralf Köhler and Heike Wulff
Molecular Pharmacology February 1, 2009, 75 (2) 281-295; DOI: https://doi.org/10.1124/mol.108.051425

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a New Activator of KCa2 and KCa3.1 Potassium Channels, Potentiates the Endothelium-Derived Hyperpolarizing Factor Response and Lowers Blood Pressure

Ananthakrishnan Sankaranarayanan, Girija Raman, Christoph Busch, Tim Schultz, Pavel I. Zimin, Joachim Hoyer, Ralf Köhler and Heike Wulff
Molecular Pharmacology February 1, 2009, 75 (2) 281-295; DOI: https://doi.org/10.1124/mol.108.051425
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Anti-aromatase activity of exemestane phase II metabolites
  • α-Conotoxin Binding Site on the GABAB Receptor
  • Upacicalcet binds to the amino acid binding site of CaSR
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics